Supernus Convertible Notes Now Convert Into 30.9355 Shares Per $1,000, Up From 24.0033
The special dividend triggers the adjustment, which sets a conversion price of about $32.33 per share, the company said.
Supernus raised the conversion rate on its 0.625% convertible notes due 2031 to 30.9355 shares per $1,000 of principal, from 24.0033, the company said in an 8-K filed Tuesday. The change follows the special dividend its board declared on September 16, 2026.
A lower price to convert
The new rate reflects a conversion price of approximately $32.33 per share, according to the filing. Each $1,000 note can now be swapped for about 6.9 more shares than before the adjustment.
The notes are the company's 0.625% Convertible Senior Notes due 2031, issued under an indenture dated March 17, 2026 with U.S. Bank Trust Company, National Association. The indenture, which the filing describes as governing the notes, required the change after the special dividend. The company is formerly known as Indivior Pharmaceuticals, Inc.
No bondholders converted their bonds into common stock, the company said.
Shares sit above the conversion price
The stock closed at $36.28 on Monday, above the $32.33 conversion price. A holder who converted at that price would receive shares worth more than the notes' face value, though the filing reports no conversions.
The filing says the conversion rate stays subject to customary adjustments under the indenture when certain events occur.
The business behind the notes
The company, listed as INDV in our records, develops prescription medicines for opioid use disorder. Its core products are Sublocade, a monthly buprenorphine injection, and Suboxone Film, which dissolves under the tongue or inside the cheek. The US accounted for 85% of net revenues for the year ended December 31, 2025, according to its annual report.
Any further change to the rate would come only from the events the indenture lists as triggers for adjustment.
Sources
- 8-K Filing — Supernus, Inc. (INDV) — SEC EDGAR